J&J touts their head-to-head win against Sanofi on MS, steer­ing an­oth­er S1P drug to the FDA

J&J in­ves­ti­ga­tors say they racked up a pos­i­tive set of num­bers for their Phase III piv­otal study of the S1P1 drug pones­i­mod in a head-to-head study against Sanofi’s Auba­gio, set­ting up a reg­u­la­to­ry fil­ing lat­er this year and a pos­si­ble launch in 2020 against some key ri­vals.

We just got the head­line re­sults — the da­ta aren’t go­ing to be re­leased un­til they can arrange that at a fu­ture sci­en­tif­ic con­fer­ence. But J&J is tout­ing re­sults for a drug that fig­ured promi­nent­ly in their $30 bil­lion Acte­lion buy­out close to 3 years ago.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER